A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Terminated · Phase 1, Phase 2 · NCT02875548
Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
At a glance
- Research payments reported, 2025
- $84,346
- U.S. investigators named
- 8
- Sites paid
- 11
- Planned or actual enrollment
- 58
About the trial
- Sponsor
- Epizyme, Inc.
- Tested
- Tazemetostat (drug)
- Dates
- Started 2016-08-30; completion 2025-09-26
- Results posted
- Yes
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy. The aim of the study will be to assess the long-term safety of tazemetostat.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Epizyme, Inc. reported $84,346 in research payments for this study in 2025 (65 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Julio C. Chavez, MD Hematology & Oncology · Tampa, FL
- Nicholas O. Iannotti, MD, FACP Hematology & Oncology · Port St Lucie, FL
- Alok Tewari, M.D., PH.D. Medical Oncology · Boston, MA
- Abhijeet Kumar Hematology & Oncology · Baltimore, MD
- Dahlia Sano, M.D. Hematology · Ann Arbor, MI
- Jennifer E. Amengual, M.D. Medical Oncology · New York, NY
- Marjorie G. Zauderer, M.D. Medical Oncology · Hawthorne, NY
- Leonard J. Appleman, MD Hematology & Oncology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Michigan $17,923
- Moffitt Cancer Center $12,518
- UPMC Cancer Center $11,160
- Banner University Cancer Center $11,160
- Hematology Oncology Associates of the Treasure Coast $10,241
- Columbia University $7,470
- University of Pittsburgh Medical Center Hillman Cancer Center $5,412
- University Arizona Cancer Ctr $4,228
- University of Michigan Hospital $2,533
- Dana-Farber Cancer Institute $1,524
- Memorial Sloan Kettering Cancer Center $177
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.